Molecular analysis of Candida glabrata clinical isolates
Norbert Berila
•
Julius Subik
Received: 28 December 2009 / Accepted: 3 March 2010 / Published online: 17 March 2010
Ó Springer Science+Business Media B.V. 2010
Abstract
Candida glabrata is an important human
pathogen, and an understanding of the genetic
relatedness of its clinical isolates is essential for the
prevention and control of fungal infections. In this
study, we determined the relatedness of 38 Candida
glabrata clinical isolates originating from two teach-
ing hospitals in Slovakia. The 14 different genotypes
were found by using microsatellite marker analysis
(RPM2, MTI and Cg6) and DNA sequencing for
analysis of the entire ERG11 gene. Subsequent
sequencing of amplified DNA fragments of the
PDR1, NMT1, TRP1 and URA3 loci in ten selected
clinical isolates revealed identical DNA sequence
profiles in five of them. They displayed the same
microsatellite marker sizes and contained the same
H576Y amino acid substitution recently described in
the Pdr1p multidrug resistance transcription factor
responsible for azole resistance. These results dem-
onstrate the genetic diversity of C. glabrata clinical
isolates in our hospitals and indicate a common
clonal origin of some drug resistant ones.
Keywords
Candida glabrata
Drug resistance
DNA sequencing
Microsatellite marker
Introduction
The haploid pathogenic yeast Candida glabrata is
considered to be the second most commonly isolated
Candida species from both bloodstream [
–
] and
vaginal infections [
–
]. It is phylogenetically closely
related to Saccharomyces cerevisiae [
], but is less
susceptible to azole antifungals when compared with
Candida albicans [
]. Therefore, the identification,
pathogenicity and epidemiology of this species are of
great importance.
Recently, we have described the susceptibilities to
fluconazole, itraconazole and voriconazole, and the
molecular mechanisms responsible for azole resis-
tance in a collection of C. glabrata clinical isolates
recovered from patients in two teaching hospitals in
Slovakia. Two amino acid substitutions, L347F and
H576Y, in the Pdr1p multidrug resistance transcrip-
tion factor were found to be associated with fluco-
nazole resistance. The same amino acid substitution
(H576Y) in Pdr1p has been identified in the 5 isolates
recovered from different patients in the same hospital
[
]. The understanding of genetic relatedness of
drug resistant clinical isolates is important for the
prevention and control of fungal infections.
Among a variety of genotyping methods utilized
for the fungal strain delineation, [
,
] are two
PCR-based methods. Multilocus sequence typing
[
–
and
microsatellite-based
multiple-locus
variable-number tandem-repeat analysis [
,
]
have been increasingly used due to their high
N. Berila
J. Subik (
&)
Department of Microbiology and Virology, Faculty of
Natural Sciences, Comenius University in Bratislava,
Mlynska dolina B-2, 842 15 Bratislava 4, Slovak Republic
e-mail: subik@fns.uniba.sk
123
Mycopathologia (2010) 170:99–105
DOI 10.1007/s11046-010-9298-1
discriminatory power relevant to C. glabrata strain
differentiation. Multilocus sequence typing relies on
DNA sequence analysis of nucleotide polymorphisms
within selected housekeeping genes [
]. Microsat-
ellite marker analysis relies on the amplification of
microsatellite
sequences
defined
as
repetitive
stretches of two to seven nucleotides in specific
genes [
,
The aim of this study was to determine the genetic
relatedness of the C. glabrata clinical isolates and
assess the relationship between their antifungal
susceptibility, molecular basis of azole resistance
and gene diversity.
Materials and Methods
Microorganisms
The 38 C. glabrata clinical isolates used in this study
were recovered from patients treated at University
Hospital in Nitra (isolates 1–28) or collected from
vaginal samples of patients in University Hospital in
Bratislava (isolates 29–38) in the years 2006 and
2007. C. glabrata ATCC 2001 (synonym CBS 138)
was used as the reference strain. The anatomical sites
of isolation and azole susceptibilities of isolates [
]
are listed in Table
. The isolates were grown at 30
°C
in complete YEPD medium (1% yeast extract, 2%
bacto-peptone and 2% glucose). When grown on
solid media, 2% agar was added to the medium.
Isolates were stored at 4
°C, subcultured as required
and stored at -80
°C in YEPD broth containing 20%
glycerol.
DNA extraction, PCR Amplification and DNA
Sequencing
Genomic DNA from isolates was extracted [
] and
used as a template for amplification of the CgERG11
gene and fragments of the CgPDR1, RPM2, MTI,
Cg6, NMT1, TRP1 and URA3 loci. PCR was carried
out with an Extensor Hi-Fidelity PCR Enzyme Kit
(ABgene, Hamburg, Germany). Sequences of primer
pairs used and their labeling are described in Table
Resulting amplicons were purified with a QIA quick
PCR Purification Kit (Qiagen, Hilden, Germany), and
the nucleotide sequences for both strands were
determined by primer elongation with an automated
DNA sequencer (ABI Prism 3100; Applied Biosys-
tems, Foster City, CA). DNA sequencing primers
were the same as those used for PCR amplification
and were supplemented with others as follows:
CgERG11-Srev 5
0
-AGGCAAGTTAGGGAAGACG
A-3
0
, CgPDR1-F3 5
0
-GGTCTTGGTTACTGTGTTC
ACCT-3
0
, CgPDR1-RI 5
0
-GACAATGGAATCGTAA
TCGCTC-3
0
, CgPDR1-F6 5
0
-TTTCTGAAGTATG
CCCTGACC-3
0
and CgPDR1-R 5
0
-CCGATAAGG-
GAGATGCAGTT-3
0
. Sequence data were compared
with genome sequences of the standard strain C. glab-
rata ATCC 2001 (synonym CBS 138;
cbi.labri.fr/Genolevures/elt/CAGL
) using the BLAST
program. For DNA fragment length analysis, the PCR
products were subjected to electrophoresis on a DNA
sequence analyzer (ABI Prism 3100; Applied Biosys-
tems, Foster City, CA) and the data analyzed with the
GeneScan software version 4.0 (Applied Biosystems,
Foster City, CA). The strain C. glabrata ATCC 2001,
with a known microsatellite pattern [
], was run as
a control in each experiment. The dendrogram of iso-
lates was constructed from the matrix of pair-wise
similarity from the 6,554 bp concatenated DNA
sequences of the ERG11, PDR1, NMT1, TRP1 and
URA3 loci using the BioNumerics software 4.1
(AppliedMath, Sint-Martens-Latem, Belgium).
Results and Discussion
To assess the genetic relatedness of 38 C. glabrata
clinical isolates listed in Table
, the microsatellite
length polymorphism was determined for 3 markers
RPM2, MTI and Cg6 selected due to their high
discriminatory power [
]. As shown in Table
the 2, 2 and 4 alleles were found for the RPM2, MTI
and Cg6 markers, respectively. Their combination
resulted in 5 different microsatellite marker size
patterns that were observed among the isolates and
the reference strain C. glabrata ATCC 2001. Most of
the isolates, 30 out of 38, exhibited two marker size
patterns. The RPM2, MTI and Cg6, 19 and 11 isolates
displayed the 128, 237, 320 and 134, 237, 315
microsatellite marker size patterns, respectively.
Each of these patterns was found in clinical isolates
which originated from the two hospitals. The same
patterns were observed among azole susceptible and
azole resistant isolates (Tables
) indicating the
100
Mycopathologia (2010) 170:99–105
123
lack of correlation between the marker size patterns
and azole resistance.
To further differentiate the isolates displaying the
same microsatellite marker size patterns, the DNA
sequence analysis of the entire ERG11 gene, known
to be polymorphic particularly in drug resistant yeast
isolates [
], was carried out. Ten different ERG11
alleles were found (Table
). The analysis, using a
Table 1
List of the
C. glabrata clinical isolates
used
S susceptible,
SDD susceptible dose
dependent, R resistant [
C. glabrata isolate
Site of isolation
In vitro susceptibility to
Fluconazole
Itraconazole
1
Endotracheal sputum
R
R
2
Urine
S
SDD
3
Tonsil
R
R
4
Urine
S
S
5
Endotracheal sputum
S
SDD
6
Tissue
S
SDD
7
Endotracheal sputum
R
R
8
Endotracheal sputum
S
SDD
9
Tongue
S
S
10
Oral cavity
S
SDD
11
Trachea
SDD
S
12
Vagina
S
SDD
13
Endotracheal sputum
SDD
SDD
14
Abscess
SDD
R
15
Endotracheal sputum
S
R
16
Tracheal canila
R
R
17
Endotracheal sputum
R
R
18
Tonsil
SDD
R
19
Tonsil
SDD
R
20
Urine
R
SDD
21
Endotracheal sputum
R
R
22
Endotracheal sputum
R
R
23
Blood
R
R
24
Endotracheal sputum
S
R
25
Trachea
R
R
26
Urine
S
R
27
Urine
R
R
28
Vagina
S
R
29
Vagina
S
R
30
Vagina
S
R
31
Vagina
SDD
R
32
Vagina
S
R
33
Vagina
SDD
R
34
Vagina
S
R
35
Vagina
SDD
R
36
Vagina
SDD
SDD
37
Vagina
S
R
38
Vagina
S
R
ATCC 2001
Reference strain
S
SDD
Mycopathologia (2010) 170:99–105
101
123
combination of 4 loci involving 3 microsatellite
markers and the ERG11 gene, resulted in identifica-
tion of 15 distinct multilocus genotypes (G1 to G15)
among the 38 clinical isolates and the reference strain
ATCC 2001. The 27 clinical isolates from different
sites of isolation recovered from different patients in
one hospital were distributed into 10 genotypes
(groups G1, G3, G4, G7-G9, G11-G14). The 11
vaginal isolates from the other hospital were distrib-
uted among 7 genotypes (groups G1, G2, G4–G6,
G10, G13). The G1, G4, and G13 genotypes
contained isolates from both hospitals.
To assess the genetic relatedness of 10 C. glabrata
isolates, investigated recently for the molecular
mechanisms involved in a decreased susceptibility
to azole antifungals [
], the combination of micro-
satellite marker analysis and DNA sequence analysis
of five genetic loci (ERG11, NMT1, TRP1, URA3 and
PDR1) was used. The 3 genetic loci NMT1, TRP1 and
URA3 were recommended for multilocus sequence
typing due to their high sequence variability [
They were supplemented with the ERG11 and PDR1
markers known to be polymorphic particularly in
drug resistant C. albicans and C. glabrata clinical
isolates [
,
]. Microsatellite marker analysis
revealed two distinct multilocus genotypes (Table
Only the Cg6 marker was discriminatory, dividing
the 10 strains into two genotypes involving two
(isolates 3 and 28) and eight (isolates 1, 7, 21, 22, 27,
29, 30 and 32) clinical isolates. Therefore, for each of
the 10 isolates, a total of 6,554 bp from ERG11 and
four additional loci (PDR1, NMT1, TRP1 and URA3)
were also sequenced. Seventeen nucleotide sites were
found to be polymorphic (Table
). The number of
polymorphic sites per locus was 7 in NMT1, followed
by 5 in PDR1, 4 in ERG11 and 1 in URA3. The
polymorphisms defined were 4 (PDR1), 3 (ERG11), 3
(NMT1) and 2 (URA3) genotypes per locus. No
polymorphism was observed in TRP1. Among the
five loci, PDR1 and ERG11 gave the highest
discrimination ratio yielding 4 and 3 different geno-
types from 5 and 4 polymorphic sites, respectively.
Table 2
Sequences and features of the primers used for amplification
Gene/
locus
GeneBank
accession no.
Primer
name
Orientation
a
Sequence (5
0
–3
0
)
Fluorescence
labeling
Reference
ERG11 L40389
ERG11-For
F
GCGATCCCTTCATGTCCATTGTC
–
[
ERG11-Rev
R
GGCTAATGAATCAGCGTATATCCCG
–
PDR1
AY700584.1
PDR1-F2
F
GTGACTCGGAAGAAAGGGAC
–
[
PDR1-Rev
R
CCGATAAGGGAGATGCAGTT
–
PDR1-F5
F
CAGAGACATCATATGAGGCAATCAG
–
PDR1-STOP R
GATATATGAATTCTCATTCAGAATCGAAGGG –
NMT1
AF073886
NMT1-For
F
GCCGGTGTGGTGTTGCCTGCTC
–
[
NMT1-Rev
R
CGTTACTGCGGTGCTCGGTGTCG
–
TRP1
U31471
TRP1-For
F
AATTGTTCCAGCGTTTTTGT
–
[
TRP1-Rev
R
GACCAGTCCAGCTCTTTCAC
–
URA3
L13661
URA3-For
F
AGCGAATTGTTGAAGTTGGTTGA
–
[
URA3-Rev
R
AATTCGGTTGTAAGATGATGTTGC
–
RPM2
AF338039
RPM2-FOR
F
ATCTCCCAACTTCTCGTAGCC
5
0
FAM
b
[
RPM2-REV
R
ACTTGAACGACTTGAACGCC
–
MTI
J05133
MTI-FOR
F
CAGCAATAATAGCTTCTGACTATGAC
5
0
FAM
b
[
MTI-REV
R
GACAGGAGCAACCGTTAGGA
–
Cg6
BZ298679
Cg6-FOR
F
AGCAAGAGGGAGGAGGAAACT
5
0
FAM
2
[
Cg6-REV
R
AAATCCGGGGATAGATGAGG
–
a
F forward primer, R reverse primer
b
FAM 6-carboxyfluorescein
102
Mycopathologia (2010) 170:99–105
123
Table
3
Genotypes
of
C.
glabrata
clinical
isolates
and
the
reference
strain
ATCC
2001
based
on
the
microsatellite
marker
analysis
and
the
ERG11
gene
sequencing
C.
glabrata
isolate
Marker
allele
size
(bp)
Base
substitution
in
the
ERG11
gene
Genotype
group
RPM2
MTI
Cg6
G87A
G90A
C192T
G296A
C539A
C588T
T768C
T834C
C918T
G927A
A1023G
T1275C
A1505T
T1557A
3,
28
128
237
315
-
-
-
-
-
-?
--
?
?
-
-
?
G1
37
128
237
315
-
-
-
-
-
-?
?-
-
?
-
-
?
G2
1,
7,
14,
15,
16,
17,
18,
19,
21,
22,
25,
27
128
237
320
-
-
-
-
-
??
-?
-
?
-
?
?
G3
4,
11,
29,
30,
32
128
237
320
-
-
-
-
-
??
-?
-
?
-
-
?
G4
31
128
237
320
-
-
-
-
-
-?
--
?
?
-
-
?
G5
33
128
237
320
-
-
-
-
-
-?
?-
-
?
-
-
?
G6
2,
20
128
237
322
?
-
?
-
-
-?
?-
-
?
-
-
?
G7
12
128
237
322
-
-
-
-
-
-?
?-
-
?
-
-
?
G8
23
128
237
322
-
-
-
-
-
-?
--
-
?
?
-
?
G9
35
128
237
322
-
-
-
-
-
-?
--
?
?
-
-
?
G10
5
134
237
315
-
?
-
-
-
-?
--
-
?
-
-
?
G11
6
134
237
315
-
?
-
?
?
-?
--
?
?
-
-
?
G12
8,
9,
10,
13,
26,
34,
36,
38
134
237
315
-
-
-
-
-
-?
--
?
?
-
-
?
G13
24
134
237
315
-
-
-
-
-
??-
--
?
-
-
?
G14
ATCC
2001
128
228
326
G
G
C
G
C
C
T
T
C
G
A
T
A
T
G15
?
,
base
substitution
present;
-
,
base
substitution
absent
Mycopathologia (2010) 170:99–105
103
123
The dendrogram indicating the relatedness of the
10 clinical isolates determined by DNA sequence
analysis with amplified fragments of 5 genes is shown
in Fig.
. Isolates 3 and 28 were differentiated on the
variable sequences in the PDR1 and NMT1 loci
(Table
). Moreover, isolate 3 was resistant to
fluconazole and itraconazole due to gain-of-function
L347F mutation in Pdr1p and is responsible for
overexpression of multidrug resistance efflux pumps
Cdr1p and Cdr2p [
]. On the other hand, the 5
fluconazole resistant isolates, 1, 7, 21, 22 and 27,
containing the H576Y amino acid substitution in
Pdr1p [
], could not be differentiated even by a
combination of microsatellite marker and DNA
sequence analyses using the genetic loci indicated.
With the exception of isolate 27 recovered from
urine, the other 4 isolates (isolates 1, 7, 21 and 22)
were all recovered from endotracheal sputum of
different patients in a 2-year period. Clinical isolates
7, 21, 22 and 1, 27 were recovered in the years 2006
and 2007, respectively. Additionally, the same azole
resistance patterns, amino acid substitutions in Pdr1p
and Erg11p, DNA sequences in the NMT1 and URA3
loci, and microsatellite marker sizes indicate a
common clonal origin of these five isolates recovered
from patients in the same hospital.
Isolates 16, 17 and 25 were recovered from trachea
in the same hospital and also displayed cross-resis-
tance to fluconazole, itraconazole and voriconazole
[
]. Based on the results of microsatellite marker
analysis and the ERG11 gene sequencing, they belong
to the same genotype as isolates 1, 7, 21, 22 and 27
(Table
). This suggests that they may harbor the same
Table
4
Polymorphisms
of
the
RPM2,
MTI,
Cg6,
PDR1,
ERG11,
NMT1
and
URA3
loci
in
the
10
azole
resistant
C.
glabrata
clinical
isolates
C.
glabrata
isolate
Marker
allele
size
(bp)
The
position
of
the
polymorphism
in
the
coding
sequence
of
the
locus
PDR1
ERG11
NMT1
URA3
RPM2
MTI
Cg6
837
1,039
1,726
2,319
2,578
588
918
927
1,505
681
744
822
955
1,221
1,238
1,246
601
1,
7,
21,
22,
27
128
237
320
C
C
T
T
C
TTG
T
A
C
A
A
CA
CG
3
128
237
315
T
T
C
T
C
C
C
A
AG
T
G
G
GAT
A
28
128
237
315
T
C
C
A
T
C
C
A
A
G
T
G
G
G
T
T
A
29,
30,
32
128
237
320
C
C
C
A
T
T
T
G
A
A
C
A
A
C
A
C
G
The
polymorphisms
indicated
by
bold
result
in
the
L347T,
H576Y
and
E502
V
amino
acid
substitutions
in
Pdr1p
and
Erg11p,
respectively
Fig. 1
Dendrogram showing the relatedness of ten C. glabrata
clinical isolates taking into account the concatenated sequences
from the ERG11, PDR1, NMT1, TRP1 and URA3 loci. Isolates
1, 3, 7, 21, 22 and 27 were resistant to fluconazole; isolates 28,
29, 30 and 32 were fluconazole sensitive
104
Mycopathologia (2010) 170:99–105
123
gain-of-function H576Y mutation in Pdr1p associated
with azole resistance. Along with these fluconazole
resistant isolates, the genotype group G3 also con-
tained clinical isolates displaying fluconazole sensi-
tivity (isolate 15) and fluconazole dose dependence
(isolates 14, 18 and 19; Table
) [
]. The microevo-
lution of C. glabrata isolates from sensitive to
fluconazole resistant ones and their clonal prolifera-
tion in one of the teaching hospitals cannot be ruled out
as the source of the recovered isolates. To our
knowledge, this is the first study presenting the genetic
relatedness of C. glabrata clinical isolates for which
the molecular mechanisms of multidrug resistance
were found to be associated with mutations in the
CgPDR1 gene.
Acknowledgments
We thank H. Drahovska for help with
BioNumerics software and D. Hanson for careful reading of the
manuscript. This work was supported by grants from the
Slovak Research and Developmental Agency (LPP-0022-06,
LPP-0011-07, VVCE-0064-07) and the Slovak Grant Agency
of Science (VEGA 1/0001/09).
References
1. Pfaller MA, Messer SA, Hollis RJ, et al. Trends in species
distribution and susceptibility to fluconazole among blood
stream isolates of Candida species in the United States.
Diagn Microbiol Infect Dis. 1999;33:217–22.
2. Diekema DJ, Messer SA, Brueggemann AB, et al. Epide-
miology of candidemia: 3-year results from the emerging
infections and the epidemiology of Iowa organisms study.
J Clin Microbiol. 2002;40:1298–302.
3. Tortorano AM, Peman J, Bernhardt H, et al. Epidemiology
of candidaemia in Europe: results of 28 month European
confederation of medical mycology (ECMM) hospital
based surveillance study. Eur J Clin Microbiol Infect Dis.
2004;23:317–22.
4. Sobel JD, Chain W. Treatment of Torulopsis glabrata
vaginitis: retrospective review of boric acid therapy. Clin
Infect Dis. 1997;24:649–52.
5. Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance
fluconazole therapy for recurrent vulvovaginal candidiasis.
N Engl J Med. 2004;351:876–83.
6. Sojakova M, Liptajova D, Borovsky M, Subik J. Fluco-
nazole and itraconazole susceptibility of vaginal isolates
from Slovakia. Mycopathologia. 2004;157:163–9.
7. Bialkova A, Subik J. Biology of the pathogenic yeast
Candida glabrata. Folia Microbiol. 2006;51:3–20.
8. Kaur R, Domerque E, Zupancic ML, Cormack BP. A yeast
by any other name: Candida glabrata and its interaction
with the host. Curr Opin Microbiol. 2005;8:378–84.
9. Sanglard D. Genomic view on antifungal resistance
mechanisms among yeast and fungal pathogens. In:
d‘Enfert Ch, Hube B, editors. Candida: comparative and
functional genomics. Norfolk: Caister Academic Press;
2007. p. 359–82.
10. Berila N, Borecka S, Dzugasova V, Bojnansky J, Subik J.
Mutations in CgPDR1 and CgERG11 genes in azole-
resistant Candida glabrata clinical isolates from Slovakia.
Int J Antimicrob Agents. 2009;33:574–8.
11. Dassanayake RS, Samaranayake LP. Amplification-based
nucleic acid scanning techniques to assess genetic poly-
morphism in Candida. Crit Rev Microbiol. 2003;29:1–24.
12. Abbes S, Amouri I, Sellami H, Sellami A, Makni F,
Ayadi A. A review of molecular techniques to type
Candida glabrata isolates. Mycoses. 2010. doi:
.
13. Dodgson AR, Pujol C, Denning DW, Soll DR, Fox AJ.
Multilocus sequence typing of Candida glabrata reveals
geographically enriched clades. J Clin Microbiol. 2003;
41:5709–17.
14. Lin CY, Chen YC, Lo HJ, Chen KW, Li SY. Assessment
of Candida glabrata strain relatedness by pulsed-field gel
electrophoresis and multilocus sequence typing. J Clin
Microbiol. 2007;45:2452–9.
15. Shin JH, Chae MJ, Song JW, et al. Changes in karyotype
and azole susceptibility of sequential bloodstream isolates
from patients with Candida glabrata candidemia. J Clin
Microbiol. 2007;45:2385–91.
16. Foulet F, Nicolas N, Eloy O, et al. Microsatellite marker
analysis as a typing system of Candida glabrata. J Clin
Microbiol. 2005;43:4574–9.
17. Grenouilllet F, Millon L, Bart JM, et al. Multiple-locus
variable-number tandem-repeat analysis for rapid typing of
Candida glabrata. J Clin Microbiol. 2007;45:3781–4.
18. Xu J, Ramos A, Vilgalys R, Mitchel TG. Clonal and
spontaneous origin of fluconazole resistance in Candida
albicans. J Clin Microbiol. 2000;38:1214–20.
19. Cernicka J, Subik J. Resistance mechanisms in fluconaz-
ole-resistant Candida albicans isolates from vaginal can-
didiasis. Int J Antimicrob Agents. 2006;27:403–8.
20. Ferrari S, Ischer F, Calabrese D, Posteraro B, Sanguinetti M,
Fadda G, et al. Gain of function mutations in CgPDR1 of
Candida glabrata not only mediate antifungal resistance but
also enhance virulence. PLoS Pathog. 2009;5(1):e1000268.
Mycopathologia (2010) 170:99–105
105
123